Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) released its quarterly earnings data on Wednesday. The company reported $0.24 earnings per share for the quarter, missing the consensus estimate of $0.25 by ($0.01), Zacks reports. Fresenius SE & Co. had a net margin of 6.67% and a return on equity of 10.33%. The company had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion.
Fresenius SE & Co. Trading Up 0.2%
Shares of FSNUY traded up $0.03 during trading hours on Friday, hitting $13.57. 3,176 shares of the stock traded hands, compared to its average volume of 151,189. The business has a fifty day moving average of $11.80 and a 200-day moving average of $12.76. The firm has a market capitalization of $30.57 billion, a PE ratio of 17.18 and a beta of 0.61. Fresenius SE & Co. has a 1-year low of $10.33 and a 1-year high of $33.93. The company has a current ratio of 1.27, a quick ratio of 0.98 and a debt-to-equity ratio of 0.41.
Analysts Set New Price Targets
FSNUY has been the subject of a number of recent analyst reports. Morgan Stanley reiterated an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a report on Thursday. Three investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has a consensus rating of “Buy”.
Fresenius SE & Co. Company Profile
Fresenius SE & Co KGaA is a global healthcare group headquartered in Bad Homburg vor der Höhe, Germany. Founded in 1912 by Eduard Fresenius, the company has grown into one of the world’s leading providers of products and services for dialysis, hospitals and outpatient medical care. Trading on major European exchanges and available over the counter in the U.S. as FSNUY, Fresenius SE & Co brings together a portfolio of specialized healthcare businesses under one corporate umbrella.
The company operates through four main business segments.
Featured Stories
- Five stocks we like better than Fresenius SE & Co.
- AST SpaceMobile’s Latest BlueBird Launch Raises the Stakes Ahead of Q2 Earnings
- Buy the Dip or Run: 3 Software Stocks Down 50% Face Their Moment of Truth
- IonQ Sparks a Quantum Grid Revolution
- No Hangover: Revisiting Microsoft One Week After Earnings
Receive News & Ratings for Fresenius SE & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
